Skip to main content
Top
Published in:

16-01-2024 | Diffuse Large B-Cell Lymphoma | Original Article

Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century

Authors: Li-Ye Bei, Chun-Yu Shang, Jia-Zhu Wu, Hao-Rui Shen, Hua Yin, Jin-Hua Liang, Xin-Yu Zhang, Li Wang, Jian-Yong Li, Yue Li, Wei Xu

Published in: Annals of Hematology | Issue 5/2024

Login to get access

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a severe non-Hodgkin’s lymphoma. Life expectancy has improved with rituximab, but cause-specific mortality data is lacking. Using the Surveillance, Epidemiology, and End Results (SEER) database to study 27,449 individuals aged 20–74 years diagnosed with primary DLBCL who received chemotherapy between 2000 and 2019, we calculated standardized mortality rate (SMR) and excess absolute risk (EAR) and examined the connection between age, sex, time after diagnosis, and cause of death. Based on 12,205 deaths, 68.7% were due to lymphoma, 20.1% non-cancer causes, and 11.2% other cancers. Non-cancer mortality rates (SMR 1.2; EAR, 21.5) increased with DLBCL compared to the general population. The leading non-cancer death causes were cardiovascular (EAR, 22.6; SMR, 1.6) and infectious (EAR, 9.0; SMR, 2.9) diseases with DLBCL. Risks for non-cancer death and solid neoplasms are highest within the first diagnosis year, then decrease. Among socioeconomic factors, being white, being married, and having a higher income were favorable factors for reducing non-cancer mortality. To improve survival, close surveillance, assessment of risk factors, and early intervention are needed.
Appendix
Available only for authorised users
Literature
8.
go back to reference Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuilleres P, Fabiani B et al (2021) Subcutaneous rituximab-minichop compared with subcutaneous rituximab-minichop plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol 39(11):1203–1213. https://doi.org/10.1200/JCO.20.02666CrossRefPubMed Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuilleres P, Fabiani B et al (2021) Subcutaneous rituximab-minichop compared with subcutaneous rituximab-minichop plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol 39(11):1203–1213. https://​doi.​org/​10.​1200/​JCO.​20.​02666CrossRefPubMed
13.
27.
go back to reference Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J et al (2019) Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. J Intern Med 285(6):681–692. https://doi.org/10.1111/joim.12889CrossRefPubMed Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J et al (2019) Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. J Intern Med 285(6):681–692. https://​doi.​org/​10.​1111/​joim.​12889CrossRefPubMed
30.
go back to reference Skurlova M, Holubova K, Kleteckova L, Kozak T, Kubova H, Horacek J et al (2023) Chemobrain in blood cancers: how chemotherapeutics interfere with the brain’s structure and functionality, immune system, and metabolic functions. Med Res Rev. https://doi.org/10.1002/med.21977 Skurlova M, Holubova K, Kleteckova L, Kozak T, Kubova H, Horacek J et al (2023) Chemobrain in blood cancers: how chemotherapeutics interfere with the brain’s structure and functionality, immune system, and metabolic functions. Med Res Rev. https://​doi.​org/​10.​1002/​med.​21977
Metadata
Title
Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century
Authors
Li-Ye Bei
Chun-Yu Shang
Jia-Zhu Wu
Hao-Rui Shen
Hua Yin
Jin-Hua Liang
Xin-Yu Zhang
Li Wang
Jian-Yong Li
Yue Li
Wei Xu
Publication date
16-01-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05619-w

Other articles of this Issue 5/2024

Annals of Hematology 5/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare